主要学习及工作经历 1986.8-1992.7 北京医科大学公卫学院预防医学专业本科 1996.8-1999.7 北京医科大学公卫学院环卫和劳卫专业硕士 1992.7-2001.8 北京医科大学公卫学院环卫和劳卫系 助教 讲师 2001.9-现在 北京大学医学部 病原生物系 讲师 副教授 2004.6 香港中文大学 工作进修 2005.8-2007.3 比利时根特大学分子生物医学系 工作进修

主要学术任职 1.北京医学会肝病学分会委员。 2.中国病毒病杂志编委。SCI期刊和国内核心期刊等审稿人。 3.中联肝健康中心理事。

获奖情况 1. 参加课题“乙型肝炎病毒病毒相关慢性肝病的基础与临床应用研究”, 获得山东科技进步奖，二等奖，2015 2.参加的课题“戊型肝炎病毒基因4型及其分子生物学和家畜感染研究”获2005年中华医学科技奖一等奖（证书号：200401075U0402）. 3.中国药品监督管理局颁发的新药证书(第三名)“新型冠状病毒(N蛋白)测定试剂盒(化学发光法)” 2004.6

研究方向 肝炎病毒病原学，分子流行病学和致病性研究

基金来源 1. “十三五”传染病重大专项计划病毒性肝炎重大研究课题“重大传染病新型诊断技术与产品研发”的任务课题“慢性乙肝相关肝纤维化／肝硬化诊断和监测：血清糖组学标志物应用于临床研究”(2017ZX10732401-003-015)。 2. HCV相关肝癌的血清糖组学标志物研究， 广西病毒性肝炎防治研究重点实验室开放课题基金项目（课题编号GXCDCKL201901）。 3. 肝纤维化血清糖组学生物标志物研究, 北京大学医学部和森隆药业合作课题（横向）。 4. 肝脏疾病相关糖组学研究, 北京大学医学部和江苏先思达生物科技有限公司合作课题（横向）。 5. “十二五”传染病重大专项计划病毒性肝炎重大研究专项（2013ZX10002004）“逆转乙肝纤维化/肝硬化及阻断疾病进展的优化治疗”任务：逆转乙肝纤维化/肝硬化优化治疗的病毒学因素研究。 6. 乙肝疫苗免疫持久性和加强免疫效果研究， 广西病毒性肝炎防治研究重点实验室开放课题基金项目（课题编号GXCDCKL201601） 7. 60微克两针程序乙肝疫苗成人免疫效果研究，北京大学医学部和深圳康泰生物制品有限公司合作课题（横向） 8. 北京大学医学部和福建广生堂药业合作课题（横向），拉米夫定和阿德福韦酯优化治疗慢性乙型肝炎的疗效观察。 9. “十一五”传染病重大专项计划病毒性肝炎重大研究专项 (2009ZX10004-314) “乙型肝炎病毒表型分析技术和耐药监测网络的建立及应用”子课题：肝内HBVcccDNA检测技术的建立及其与耐药的相关性研究。 10. 北京大学医学部与北京科兴生物制品公司合作课题（横向），甲型肝炎灭活疫苗和减毒活疫苗在儿童和成人中免疫原性及免疫持久性研究。 11. 中国科技部和比利时合作课题，Prediction of liver disease with serum protein glycomics: non-invasive diagnosis of liver fibrosis,cirrhosis and hepatocellular carcinoma. 12. 北京市科委课题：病毒性肝炎临床诊断与治疗的一体化研究(H020920020190).

代表论文 1. Gao YH, Yang J, Sun F, Zhan SY, Fang ZL, Liu XE, Zhuang H. Prevalence of anti-HCV antibody among the general population in Mainland China between 1991 and 2015: a systematic review and meta-analysis. Open Forum infectious diseases 2019; 6(3):ofz040(1-7). 2. Wang L, Lu W, Gao YH, Yan HJ, Pei F, Liu XE, Zhuang H. Anluohuaxianwan alleviates CCL4-induced hepatic fibrosis in rats through upregulation of PPARγ and downregulation of NF-κB/IκBα signaling pathway. World Journals of Traditional Chinese Medicine 2019; 5(2):95-103. 3. Wang L, Cao X, Wang ZZ, Gao YH, Deng J, Liu XE, Zhuang H . Correlation of HBcrAg with intrahepatic hepatitis B virus total DNA and covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients Journal of clinical microbiology 2018, 57:e01303-18. 4. Wang ZZ, Gao YH, Wang P, Wei L, Xie CP, Yang ZX, Lan J, Fang ZL, Zeng Y, Yan L, Liu XE, Zhuang H. Comparison of immunogenicity between hepatitis B vaccine with different dosages and schedules among healthy young adults in China: A 2-year follow-up study Human vaccines and immunotherapeutics 2018;14(6):1475-1482. 5. Gao YH, Li YT, Meng QH, Zhang ZQ, Zhao P, Shang QH, Li Y, Su MZ, Li T, Liu XE, Zhuang H. Serum hepatitis B virus DNA, RNA, and HBsAg: which correlated better with intrahepatic covalently closed circular DNA before and after nucleos(t)ide analogue treatment? Journal of clinical microbiology 2017; 55(10): 2972-2982. 6. Wang ZZ, Gao YH, Lu W, Jin CD, Zeng Y, Yan L, Ding F, Li T, Liu XE, Zhuang H. Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China Human vaccines and immunotherapeutics 2017; 13(4): 909-915. doi:10.1080/21645515.2016.1250990 (IF: 2.146) 7. Xiang KH, Michailidis E, Ding H, Peng YQ, Su MZ, Li Y, Liu XE, Dao Thi VL, Wu XF, Schneider WM, Rice CM, Zhuang H, Li T. Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA Journal of Hepatology 2017; 66(2):288-296. 8. Gao YH, Meng QH, Zhang ZQ, Zhao P, Shang QH, Yuan Q, Li Y, Deng J, Li T, Liu XE, Zhuang H. On-treatment quantitative HBeAg predicted response to nucleos(t)ide analogues in chronic hepatitis B World journal of hepatology 2016; 8(34): 1511-1520. 9. Wang ZZ, Li MQ, Wang P, Yang ZX, Wei L, Zeng Y, Li YP, Yan L, Liu XE, Zhuang H. Comparative immunogenicity of hepatitis B vaccine with different dosages and schedules in healthy adults in China. Vaccine. 2016; 34:1034-1039. 10. Li Y, Huang YS, Wang ZZ, Sun F, Zhan SY, Liu XE, Zhuang H. Systematic Review with Meta-analysis: The Diagnostic Accuracy of Transient Elastography for the Staging of Liver Fibrosis in Patients with Chronic Hepatitis B. Alimentary Pharmacology & Therapeutics. 2016; 43:458-469. 11. Duan PW, Lu SC,Lai W, Liu XE, Liu Y. The detection of (total and ccc) HBV DNA in liver transplant recipients with hepatitis B vaccine against HBV reinfection. Hum Vaccin Immunother. 2015; 11(10):2490-4. . 12. Liu XE, Chen HY, Liao Z, Zhou YS, Wen HR, Peng SH, Liu Y, Li R, Li J, Zhuang H. Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines among young adults: a three-year follow-up study, Journal of Infectious Diseases Journal of Infectious Diseases. 2015, 212(8): 1232-1236. 13. Qiu N, Li R, Yu JG,Yang W, Zhang W, An Y, Li T, Liu XE, Zhuang H. Comparison of Abbott and Da-an real-time PCR assays for quantitating serum HBV DNA. World journal of gastroenterology 2014; 20（33）11762-11769. 14. Liu XE, Wushouer F, Gou AL, Kuerban M, Li XL, Sun YB, Zhang JM, Liu Y, Li J, Zhuang H. Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines: a single-blind, randomized, parallel-group clinical trial among children in Xinjiang Uighur Autonomous Region, China. Human Vaccines and Immunotherapeutics 2013，9（7）：1-6. 15. Wang MR, Qiu N, Lu SC, Xiu DR, Yu JG, Wang XT, Lu FM, Li T, Liu XE, Zhuang H. Serum hepatitis B surface antigen is correlated with intrahepatic total HBV DNA and cccDNA in treatment-Naïve patients with chronic hepatitis B but not in patients with HBV related hepatocellular carcinoma. Journal of Medical Virology. 2013, 85(2): 219-227. 16. Li XG, Liu BM, Xu J, Liu XE, Ding H, Li T. Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogue-untreated and -treated patients with chronic hepatitis B in a hospital in China. J Medical Virology. 2012, 84(2): 207-16. 17. Liu XE, Dewaele.S, Vanhooren V, Fan YD, Wang L, Van Huysse J, Zhuang H, Contreras R, Libert C, Chen CY. Alteration of N-glycome in diethylnitrosamine-induced hepatocellular carcinoma mice :a non-invasive monitoring tool for liver cancer. Liver International. 2010,30(8):1221-8. 18. Gui HL, Gao CF, Wang H, Liu XE, Xie Q, Dewaele S, Wang L, Zhuang H, Contreras R, Libert C, Chen C. Altered serum N-glycomics in chronic hepatitis B patients. Liver International. 2010, 30(2):259-67. 19. Chen C, Schmilovitz-Weiss H, Liu XE, Pappo O, Halpern M, Sulkes J, Braun M, Cohen M, Barak N, Tur-Kaspa R, Vanhooren V, Van Vlierberghe H, Libert C, Contreras R, Ben-Ari Z. Serum Protein N-Glycans Profiling for the Discovery of Potential Biomarkers for Nonalcoholic Steatohepatitis. Journal of Proteome Research. 2009, 8(2): 463-470. 20. Vanhooren V, Liu XE, Franceschi C, Gao CF, Libert C, Contreras R, Chen C. N-glycan profiles as tools in diagnosis of hepatocellular carcinoma and prediction of healthy human ageing. Mech Ageing Dev. 2009, 130(1-2): 92-7. 21. Vanhooren V, Liu XE, Desmyter L, Fan YD, Vanwalleghem L, Van Molle W, Dewaele S, Praet M, Contreras R, Libert C, Chen C. Over-expression of heat shock protein 70 in mice is associated with growth retardation, tumor formation, and early death. Rejuvenation Research. 2008, 11(6): 1013-20. 22. Liu XE, Desmyter L, Gao CF, Laroy W, Dewaele S, Vanhooren V, Wang L, Zhuang H, Callewaert N, Libert C, Contreras R, Chen C. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology. 2007, 46(5):1426-1435. 23. Vanhooren V, Desmyter L, Liu XE, Cardelli M, Franceschi C, Federico A, Libert C, Laroy W, Dewaele S, Contreras R, Chen CY. N-glycomic changes in serum proteins during human ageing. Rejuvenation Research, 2007, 10(4):521-531. 24. Li YH, Li J, Liu XE, Wang L, Li T, Zhou YH, Zhuang H. Detection of the nucleocapsid protein of severe acute respiratory syndrome coronavirus in serum: Comparison with results of other viral markers. J Virology Methods, 2005, 130(1-2):45-50.